IntraBiotics Protegrin IB-367 Rinse
Executive Summary
Collaborative development and marketing agreement with Pharmacia & Upjohn is terminated and global rights to market the topical antimicrobial rinse returned to IntraBiotics, the Mountain View, Calif.-based company announced Aug. 10. Under an October 1997 agreement, the companies were jointly developing Protegrin IB-367 rinse for the treatment and prevention of oral mucositis in the U.S; P&U had exclusive rights in all other markets. P&U's decision is related to Protegrin's potential market size relative to P&U's product pipeline, IntraBiotics said. The product has completed Phase II trials, and Phase III studies are expected to begin in the first half of 2000